vs
车车集团（CCG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
车车集团的季度营收约是REGENXBIO Inc.的1.1倍（$32.8M vs $30.3M），车车集团净利率更高（0.5% vs -221.3%，领先221.8%）
车车集团是国内领先的汽车数字化服务提供商，主营汽车保险中介服务、智能汽车售后支持、车联网技术产品等业务，服务覆盖个人车主、汽车经销商及保险合作机构，部分业务辐射东南亚市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CCG vs RGNX — 直观对比
营收规模更大
CCG
是对方的1.1倍
$30.3M
净利率更高
CCG
高出221.8%
-221.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.8M | $30.3M |
| 净利润 | $153.6K | $-67.1M |
| 毛利率 | 5.7% | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 0.5% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.00 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCGRGNX
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | $26.0M | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | $18.6M | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | $36.1M | $22.3M |
净利润CCGRGNX
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | $-67.1M | ||
| Q3 25 | — | $-61.9M | ||
| Q2 25 | $-492.4K | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | $-196.7K | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | $-7.6M | $-53.0M |
毛利率CCGRGNX
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.2% | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | 4.3% | 52.5% |
营业利润率CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | -2.0% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | -0.3% | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | -4.7% | -251.3% |
净利率CCGRGNX
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | -221.3% | ||
| Q3 25 | — | -208.3% | ||
| Q2 25 | -1.9% | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | -1.1% | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | -21.0% | -237.7% |
每股收益（稀释后）CCGRGNX
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | $-0.01 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | $-0.00 | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $230.1M |
| 总债务越低越好 | $193.3K | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | $203.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCGRGNX
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | $23.1M | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $21.1M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | $28.2M | $290.4M |
总债务CCGRGNX
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $690.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $102.7M | ||
| Q3 25 | — | $161.5M | ||
| Q2 25 | $47.1M | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | $49.1M | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | $48.6M | $348.3M |
总资产CCGRGNX
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $453.0M | ||
| Q3 25 | — | $525.2M | ||
| Q2 25 | $177.3M | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | $177.7M | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | $139.3M | $569.4M |
负债/权益比CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.3M | ||
| Q3 25 | — | $-56.0M | ||
| Q2 25 | $-44.7M | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | $-15.8M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | $-1.0K | $-45.5M |
自由现金流CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $-16.0M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | $-1.1K | $-46.0M |
自由现金流率CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | -85.9% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | -0.0% | -206.2% |
资本支出强度CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 1.2% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 0.0% | 2.1% |
现金转化率CCGRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCG
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
